Suppression	0	11	O
of	12	14	O
lung	15	19	B-Pathological_formation
tumor	20	25	I-Pathological_formation
growth	26	32	O
and	33	36	O
metastasis	37	47	O
in	48	50	O
mice	51	55	B-Organism
by	56	58	O
adeno	59	64	B-Organism
-	64	65	I-Organism
associated	65	75	I-Organism
virus	76	81	I-Organism
-	81	82	O
mediated	82	90	O
expression	91	101	O
of	102	104	O
vasostatin	105	115	B-Gene_or_gene_product
.	115	116	O

PURPOSE	118	125	O
:	125	126	O
Angiogenesis	127	139	O
inhibitors	140	150	O
have	151	155	O
strong	156	162	O
therapeutic	163	174	O
potential	175	184	O
as	185	187	O
antitumor	188	197	B-Pathological_formation
agents	198	204	O
in	205	207	O
suppressing	208	219	O
tumor	220	225	B-Pathological_formation
growth	226	232	O
and	233	236	O
metastatic	237	247	O
progression	248	259	O
.	259	260	O

Vasostatin	261	271	B-Gene_or_gene_product
,	271	272	O
the	273	276	O
N	277	278	O
-	278	279	O
terminal	279	287	O
domain	288	294	O
of	295	297	O
calreticulin	298	310	B-Gene_or_gene_product
,	310	311	O
is	312	314	O
a	315	316	O
potent	317	323	O
angiogenesis	324	336	O
inhibitor	337	346	O
.	346	347	O

In	348	350	O
this	351	355	O
study	356	361	O
,	361	362	O
we	363	365	O
determined	366	376	O
the	377	380	O
effectiveness	381	394	O
of	395	397	O
vasostatin	398	408	B-Gene_or_gene_product
delivered	409	418	O
by	419	421	O
recombinant	422	433	B-Organism
pseudotype	434	444	I-Organism
adeno	445	450	I-Organism
-	450	451	I-Organism
associated	451	461	I-Organism
virus	462	467	I-Organism
2	468	469	I-Organism
/	469	470	O
5	470	471	B-Organism
(	472	473	O
rAAV2	473	478	B-Organism
/	478	479	O
5	479	480	B-Organism
-	480	481	I-Organism
VAS	481	484	I-Organism
)	484	485	O
as	486	488	O
a	489	490	O
gene	491	495	O
therapy	496	503	O
approach	504	512	O
for	513	516	O
lung	517	521	B-Pathological_formation
cancer	522	528	I-Pathological_formation
treatment	529	538	O
.	538	539	O

EXPERIMENTAL	540	552	O
DESIGN	553	559	O
:	559	560	O
We	561	563	O
used	564	568	O
rAAV2	569	574	B-Organism
/	574	575	O
5	575	576	B-Organism
to	577	579	O
deliver	580	587	O
vasostatin	588	598	B-Gene_or_gene_product
intratumorally	599	613	B-Pathological_formation
or	614	616	O
systemically	617	629	O
in	630	632	O
different	633	642	O
mouse	643	648	B-Organism
lung	649	653	B-Pathological_formation
tumor	654	659	I-Pathological_formation
models	660	666	O
-	666	667	O
-	667	668	O
subcutaneous	668	680	O
,	680	681	O
orthotopic	682	692	O
xenograft	693	702	O
,	702	703	O
and	704	707	O
spontaneous	708	719	O
metastasis	720	730	O
lung	731	735	B-Pathological_formation
tumor	736	741	I-Pathological_formation
models	742	748	O
.	748	749	O

The	750	753	O
therapeutic	754	765	O
efficacy	766	774	O
of	775	777	O
rAAV2	778	783	B-Organism
/	783	784	O
5	784	785	B-Organism
-	785	786	I-Organism
VAS	786	789	I-Organism
was	790	793	O
determined	794	804	O
by	805	807	O
monitoring	808	818	O
tumor	819	824	B-Pathological_formation
volume	825	831	O
,	831	832	O
survival	833	841	O
rate	842	846	O
,	846	847	O
and	848	851	O
degree	852	858	O
of	859	861	O
neovascularization	862	880	O
after	881	886	O
treatment	887	896	O
in	897	899	O
these	900	905	O
models	906	912	O
.	912	913	O

RESULTS	914	921	O
:	921	922	O
Mice	923	927	B-Organism
bearing	928	935	O
subcutaneous	936	948	B-Pathological_formation
tumor	949	954	I-Pathological_formation
of	955	957	O
rAAV2	958	963	B-Organism
/	963	964	O
5	964	965	B-Organism
-	965	966	I-Organism
VAS	966	969	I-Organism
pretreated	970	980	O
Lewis	981	986	B-Cell
lung	987	991	I-Cell
carcinoma	992	1001	I-Cell
cells	1002	1007	I-Cell
showed	1008	1014	O
>	1015	1016	O
50	1016	1018	O
%	1018	1019	O
reduction	1020	1029	O
in	1030	1032	O
primary	1033	1040	O
tumor	1041	1046	B-Pathological_formation
volume	1047	1053	O
and	1054	1057	O
reduced	1058	1065	O
spontaneous	1066	1077	O
pulmonary	1078	1087	B-Organ
metastases	1088	1098	O
.	1098	1099	O

The	1100	1103	O
tumor	1104	1109	O
-	1109	1110	O
suppressive	1110	1121	O
action	1122	1128	O
of	1129	1131	O
rAAV2	1132	1137	B-Organism
/	1137	1138	O
5	1138	1139	B-Organism
-	1139	1140	I-Organism
VAS	1140	1143	I-Organism
in	1144	1146	O
subcutaneous	1147	1159	O
human	1160	1165	B-Organism
lung	1166	1170	B-Pathological_formation
tumor	1171	1176	I-Pathological_formation
A549	1177	1181	I-Pathological_formation
xenograft	1182	1191	I-Pathological_formation
correlated	1192	1202	O
with	1203	1207	O
a	1208	1209	O
reduced	1210	1217	O
number	1218	1224	O
of	1225	1227	O
capillary	1228	1237	B-Tissue
vessels	1238	1245	I-Tissue
in	1246	1248	O
tumors	1249	1255	B-Pathological_formation
.	1255	1256	O

In	1257	1259	O
the	1260	1263	O
orthotopic	1264	1274	O
xenograft	1275	1284	O
model	1285	1290	O
,	1290	1291	O
rAAV2	1292	1297	B-Organism
/	1297	1298	O
5	1298	1299	B-Organism
-	1299	1300	I-Organism
VAS	1300	1303	I-Organism
suppressed	1304	1314	O
metastasis	1315	1325	O
of	1326	1328	O
A549	1329	1333	B-Pathological_formation
tumors	1334	1340	I-Pathological_formation
to	1341	1343	O
mediastinal	1344	1355	O
lymph	1356	1361	B-Multi-tissue_structure
nodes	1362	1367	I-Multi-tissue_structure
and	1368	1371	O
contralateral	1372	1385	O
lung	1386	1390	B-Organ
.	1390	1391	O

Furthermore	1392	1403	O
,	1403	1404	O
treatment	1405	1414	O
of	1415	1417	O
immunocompetent	1418	1433	O
mice	1434	1438	B-Organism
in	1439	1441	O
the	1442	1445	O
spontaneous	1446	1457	O
lung	1458	1462	B-Pathological_formation
metastases	1463	1473	I-Pathological_formation
model	1474	1479	O
with	1480	1484	O
rAAV2	1485	1490	B-Organism
/	1490	1491	O
5	1491	1492	B-Organism
-	1492	1493	I-Organism
VAS	1493	1496	I-Organism
after	1497	1502	O
primary	1503	1510	O
tumor	1511	1516	B-Pathological_formation
excision	1517	1525	O
prolonged	1526	1535	O
their	1536	1541	O
median	1542	1548	O
survival	1549	1557	O
from	1558	1562	O
21	1563	1565	O
to	1566	1568	O
51	1569	1571	O
.	1571	1572	O
5	1572	1573	O
days	1574	1578	O
.	1578	1579	O

CONCLUSION	1580	1590	O
:	1590	1591	O
Our	1592	1595	O
results	1596	1603	O
show	1604	1608	O
the	1609	1612	O
effectiveness	1613	1626	O
of	1627	1629	O
rAAV2	1630	1635	B-Organism
/	1635	1636	O
5	1636	1637	B-Organism
-	1637	1638	I-Organism
VAS	1638	1641	I-Organism
as	1642	1644	O
an	1645	1647	O
angiogenesis	1648	1660	O
inhibitor	1661	1670	O
in	1671	1673	O
suppressing	1674	1685	O
tumor	1686	1691	B-Pathological_formation
growth	1692	1698	O
during	1699	1705	O
different	1706	1715	O
stages	1716	1722	O
of	1723	1725	O
tumor	1726	1731	B-Pathological_formation
progression	1732	1743	O
,	1743	1744	O
validating	1745	1755	O
the	1756	1759	O
application	1760	1771	O
of	1772	1774	O
rAAV2	1775	1780	B-Organism
/	1780	1781	O
5	1781	1782	B-Organism
-	1782	1783	I-Organism
VAS	1783	1786	I-Organism
gene	1787	1791	O
therapy	1792	1799	O
in	1800	1802	O
treatment	1803	1812	O
against	1813	1820	O
lung	1821	1825	B-Pathological_formation
cancer	1826	1832	I-Pathological_formation
.	1832	1833	O

